Introduction
Pancreatic ductal adenocarcinoma (PDAC) is characterized by intense fibrosis which enhances the tumor growth and drives an epithelial-mesenchymal transition. The consequence is the uncontrolled proliferation of cancer cells, including pancreatic cancer stem cells (PCSC), which may enhance the metastatic potential.
Aims & Methods
The aim of this study is to assess the prognosis of CD44, CD24 and EpCAM expression, on pancreatic endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) specimens.
A total of 35 patients diagnosed with PDAC after EUS-FNB within the Research Center of Gastroenterology and Hepatology of Craiova, were included in the study, and the samples were sent for immunohistochemical assessment. A total of three passes were performed on every PDAC tumor, to harvest enough tissue for analysis. Anti-Human CD 24 (policlonal, Abcam, ab 199140) and EpCAm (Epr 20532-225, Rb monoclonal, Abcam, ab 223582) and Human CD 44 (clone DF 1485, Agilent Tehnologies Denmark, cod M7082) were used. The slides were incubated with primary antibodies for 30 minutes at room temperature. Immunolabeling in the study group was considered positive if more than 10% of tumor cells showed a present signal and negative if less than 10% of tumor cells were immunolabeled. The intensity of immunolabeling in positive cases was assessed as weak (1), moderate (2), and intensely positive (3).
Results
We assessed a total of 300 fields and 54 (18%) were assessed as triple positive, however when all three were positive no correlations were found. The expression of CD44+ ⁄ CD24+ expression was significantly correlated with poorer outcomes (P = 0.05), whereas CD44+ ⁄EpCAM+, CD24+ ⁄EpCAM+, CD44+, CD24+, or Ep-CAM+ expression did not correlate with patient’s evolution. Among the patient characteristics, T stage and N stage were significantly correlated with poorer prognosis. CD44 and CD24 were significantly correlated with poor differentiation and high proliferation which might suggest their association with cancer aggressiveness, whereas EpCAM was correlated with well differentiation and low proliferation. When comparing patients with metastasis at the time of diagnosis, CD44+ ⁄ CD24+ expression was more intense when M1 was present (p<0.005), suggesting their prognostic role. Survival analysis showed there was no correlation with the PCSC staining.
Conclusion
EUS-FNB PSCS with CD44 + /CD24+ testing might be considered for PDAC assessment as their positivity might be correlated with a poorer outcome. They might be considered for prognosis purposes at the time of diagnosis as EUS-FNB might provide significant tissue for analysis, thus suggesting their possible therapeutic value in a clinical setting.
Disclosure
No conflicts of interest